Contract notice
Section I: Contracting
authority
I.1) Name and addresses
The Common Services Agency (more commonly known as NHS National Services Scotland) (‘the Authority’)
Gyle Square (NSS Head Office), 1 South Gyle Crescent
Edinburgh
EH12 9EB
UK
Contact person: Siobhan Ramage
Telephone: +44 1698794547
E-mail: siobhan.ramage@nhs.net
NUTS: UKM
Internet address(es)
Main address: http://www.nhsscotlandprocurement.scot.nhs.uk/
Address of the buyer profile: http://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge at:
https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be sent electronically to:
https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Antibiotic and Genito Urinary Branded and Generic Medicines
Reference number: NP36120
II.1.2) Main CPV code
33600000
II.1.3) Type of contract
Supplies
II.1.4) Short description
This framework agreement is for the supply of Antibiotic and Genito Urinary Branded and Generic Medicines to health boards across NHS Scotland.
The Goods have been split into three (3) categories, each of which is identified as a ‘Lot’. Full details of each Lot is contained in Section II.2) of this notice.
II.1.5) Estimated total value
Value excluding VAT:
52 425 627.00
GBP
II.1.6) Information about lots
This contract is divided into lots:
Yes
Tenders may be submitted for all lots
II.2) Description
Lot No: 1
II.2.1) Title
All Antibiotic and Genito Urinary Branded and Generic Medicines
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKM
Main site or place of performance:
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Description of the procurement
Supply of all antibiotic and genito urinary branded and generic medicines to NHS Scotland in a range of presentations. The Authority intends awarding a single supplier framework agreement on a line by line basis. Full details can be found within the ITT.
II.2.5) Award criteria
Criteria below:
Quality criterion: Logistics
/ Weighting: 5
Price
/ Weighting:
95
II.2.6) Estimated value
Value excluding VAT:
50 846 718.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This framework includes the option(s) to extend for up to a total period of twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.12) Information about electronic catalogues
Tenders must be presented in the form of electronic catalogues or include an electronic catalogue
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 2
II.2.1) Title
Antibiotic and Genito Urinary Medicines for CIVAS Use
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKM
Main site or place of performance:
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Description of the procurement
The supply of antibiotic and genito urinary medicines for use in the provision of Central Intravenous Additives Service (CIVAS) within health boards. The Authority intends awarding a single supplier framework agreement on a line by line basis. Full details can be found within the ITT.
II.2.5) Award criteria
Criteria below:
Quality criterion: Stability
/ Weighting: 30
Price
/ Weighting:
70
II.2.6) Estimated value
Value excluding VAT:
922 980.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This framework includes the option(s) to extend for up to a total period of twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.12) Information about electronic catalogues
Tenders must be presented in the form of electronic catalogues or include an electronic catalogue
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 3
II.2.1) Title
Tobramycin, Colistemethate and Dornase Alfa for Inhalation
II.2.2) Additional CPV code(s)
33660000
II.2.3) Place of performance
NUTS code:
UKM
Main site or place of performance:
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Description of the procurement
Supply of Tobramycin, Colistemethate and Dornase Alfa in a range of presentations to NHS Scotland. The Authority intends awarding each product line as a multi supplier unranked framework agreement on a line by line basis to an envisaged maximum of six (6) Framework Participants. Full details can be found within the ITT.
II.2.5) Award criteria
Criteria below:
Quality criterion: Logistics
/ Weighting: 5
Price
/ Weighting:
95
II.2.6) Estimated value
Value excluding VAT:
655 929.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This framework includes the option(s) to extend for up to a total period of twelve (12) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.12) Information about electronic catalogues
Tenders must be presented in the form of electronic catalogues or include an electronic catalogue
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section III: Legal, economic, financial and technical information
III.1) Conditions for participation
III.1.1) Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers
List and brief description of conditions:
Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in Regulation 58 of the Public Contracts (Scotland) Regulations 2015.
III.1.3) Technical and professional ability
List and brief description of selection criteria:
(a) potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by approved by the MHRA for all tendered Medicines at the date of framework start date;
(b) potential framework participants and any subcontractor(s) must possess valid certification of BS EN ISO 9001 or equivalent;
(c) all tendered Goods must comply with the MHRA best practice guidance on labelling and Packaging and the National Patient Safety Agency (‘NPSA’) guidelines on packaging and labelling on pack design;
(d) potential framework participants must be able to confirm that any goods submitted and classed as medical devices carry CE declaration of conformity, in compliance with the Medical Device Directive 93/42/EEC, at the date of the tender submission.
Minimum level(s) of standards required:
(a) confirmation of existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender should be included in the qualification envelope of the ITT under the technical and professional ability: quality control;
(b) confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the qualification envelope of the ITT under technical and professional ability: quality assurance schemes;
(c) confirmation that samples for tendered goods will be supplied upon request to ensure compliance with the MHRA best practice guidance on labelling and packaging and the National Patient Safety Agency (‘NPSA’) guidelines on packaging and labelling on pack design. Confirmation of sample provision should be provided in the qualification envelope of the ITT under technical and professional ability: products;
(d) confirmation that any products submitted and classed as medical devices carry a current and valid CE declaration of conformity, complying with Medical Device Directive 93/42/EEC at the date of submission of the tender should be included in the qualification envelope of the ITT under the technical and professional ability: quality control.
III.2) Conditions related to the contract
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement with several operators.
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.2) Time limit for receipt of tenders or requests to participate
Date:
10/01/2020
Local time: 12:00
IV.2.4) Languages in which tenders or requests to participate may be submitted
EN
IV.2.6) Minimum time frame during which the tenderer must maintain the tender
Duration in months: 3 (from the date stated for receipt of tender)
IV.2.7) Conditions for opening of tenders
Date:
10/01/2020
Local time: 12:00
Section VI: Complementary information
VI.1) Information about recurrence
This is a recurrent procurement:
No
VI.2) Information about electronic workflows
Electronic ordering will be used
Electronic invoicing will be accepted
Electronic payment will be used
VI.3) Additional information
The estimated values referred to in Section II.I.5) and all lots cover the twenty-four (24) months framework duration and the twelve (12) month extension period of the framework agreement.
The buyer is using PCS-Tender to conduct this ITT exercise. The project code is 15055. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343
The contracting authority does not intend to include a subcontract clause as part of community benefits (as per Section 25 of the Procurement Reform (Scotland) Act 2014) in this contract for the following reason:
It is not envisaged that sub-contractors will be utilised in delivery of this framework agreement.
The contracting authority does not intend to include any community benefit requirements in this contract for the following reason:
No community benefits will be deliverable through the award of this framework agreement.
(SC Ref:604398)
VI.4) Procedures for review
VI.4.1) Review body
The Common Services Agency (more commonly known as NHS National Services Scotland) (‘the Authority’)
Gyle Square (NSS Head Office), 1 South Gyle Crescent
Edinburgh
EH12 9EB
UK
Telephone: +44 1698794410
Internet address(es)
URL: http://www.nhsscotlandprocurement.scot.nhs.uk/
VI.4.3) Review procedure
Precise information on deadline(s) for review procedures:
The Authority will notify economic operators who submitted a tender or (where no deselection notification has previously been made) applied to be selected to tender, of its decision to award the framework agreement which notification will contain among other information, a summary of the reasons why the economic operator was unsuccessful. The notification will incorporate a 'standstill period' of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority despatches the notice(s) and the date on which the Authority proposes to conclude the relevant framework agreement. The bringing of court proceedings against the Authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer(s). The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.
VI.5) Date of dispatch of this notice
26/11/2019